• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
[Clinical observation of standard IA regimen as induction chemotherapy in 242 patients with newly diagnosed acute myeloid leukemia].[标准IA方案作为242例新诊断急性髓系白血病患者诱导化疗的临床观察]
Zhonghua Xue Ye Xue Za Zhi. 2018 Apr 14;39(4):331-335. doi: 10.3760/cma.j.issn.0253-2727.2018.04.016.
2
[Efficacy and safety analysis of different dose idarubicin plus cytarabine regimen as induction chemotherapy for young patients with de-novo acute myeloid leukemia].不同剂量去甲氧柔红霉素联合阿糖胞苷方案作为初治年轻急性髓系白血病患者诱导化疗的疗效与安全性分析
Zhonghua Xue Ye Xue Za Zhi. 2016 Aug 14;37(8):682-7. doi: 10.3760/cma.j.issn.0253-2727.2016.08.010.
3
Comparison of efficacy between homoharringtonine, aclarubicin, cytarabine (HAA) and idarubicin, cytarabine (IA) regimens as induction therapy in patients with de novo core binding factor acute myeloid leukemia.阿糖胞苷和高三尖杉酯碱（HAA）与阿糖胞苷和伊达比星（IA）方案作为初治核心结合因子急性髓系白血病患者诱导治疗的疗效比较。
Ann Hematol. 2023 Oct;102(10):2695-2705. doi: 10.1007/s00277-023-05400-5. Epub 2023 Aug 12.
4
[Clinical Efficacy of Decitabine-Based Chemotherapy Regimens in the Treatment of Newly Diagnosed Elderly Patients with Acute Myeloid Leukemia].[地西他滨化疗方案治疗新诊断老年急性髓系白血病的临床疗效]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2018 Jun;26(3):743-749. doi: 10.7534/j.issn.1009-2137.2018.03.019.
5
[Clinical curative efficacy of inducing remission for the newly diagnosed aged AML patients by chemotherapy with IA and DA regimens].
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014 Oct;22(5):1282-5. doi: 10.7534/j.issn.1009-2137.2014.05.018.
6
Comparison of Reduced-Intensity Idarubicin and Daunorubicin Plus Cytarabine as Induction Chemotherapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.低剂量伊达比星与柔红霉素加阿糖胞苷作为新诊断急性髓系白血病老年患者诱导化疗的比较
Clin Drug Investig. 2017 Feb;37(2):167-174. doi: 10.1007/s40261-016-0469-9.
7
Clinical efficacy of decitabine in combination with standard-dose cytarabine, aclarubicin hydrochloride, and granulocyte colony-stimulating factor in the treatment of young patients with newly diagnosed acute myeloid leukemia.地西他滨联合标准剂量阿糖胞苷、盐酸阿克拉霉素及粒细胞集落刺激因子治疗新诊断年轻急性髓系白血病患者的临床疗效
Onco Targets Ther. 2019 Jun 28;12:5013-5023. doi: 10.2147/OTT.S200005. eCollection 2019.
8
[Comparison of 10 mg/m² or 8 mg/m² idarubicin plus cytarabine regimen as induction chemotherapy for adult patients with newly diagnosed acute myeloid leukemia].[10mg/m²或8mg/m²伊达比星联合阿糖胞苷方案作为新诊断成人急性髓系白血病诱导化疗的比较]
Zhonghua Xue Ye Xue Za Zhi. 2015 Mar;36(3):225-9. doi: 10.3760/cma.j.issn.0253-2727.2015.03.011.
9
The efficacy and safety of daunorubicin versus idarubicin combined with cytarabine for induction therapy in acute myeloid leukemia: A meta-analysis of randomized clinical trials.柔红霉素与伊达比星联合阿糖胞苷用于急性髓性白血病诱导治疗的疗效与安全性：一项随机临床试验的荟萃分析
Medicine (Baltimore). 2020 Jun 12;99(24):e20094. doi: 10.1097/MD.0000000000020094.
10
[Efficacy of Decitabine Combined with Preexcitation Regimen in Treatment of Newly Diagnosed AML Patients Who Did not Respond to Initial Standard Induction Chemotherapy].地西他滨联合预激方案治疗初诊标准诱导化疗无效的急性髓系白血病患者的疗效
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2024 Jun;32(3):679-684. doi: 10.19746/j.cnki.issn.1009-2137.2024.03.005.

本文引用的文献

1
Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups.高剂量柔红霉素在急性髓系白血病诱导治疗中的益处涵盖细胞遗传学和分子学分组。
Blood. 2016 Mar 24;127(12):1551-8. doi: 10.1182/blood-2015-07-657403. Epub 2016 Jan 11.
2
Comparison of 60 or 90 mg/m(2) of daunorubicin in induction therapy for acute myeloid leukemia with intermediate or unfavorable cytogenetics.柔红霉素60或90mg/m²用于细胞遗传学处于中等或不良状态的急性髓系白血病诱导治疗的比较。
Am J Hematol. 2015 Feb;90(2):E29-30. doi: 10.1002/ajh.23884. Epub 2014 Nov 19.
3
Acute myeloid leukemia in the real world: why population-based registries are needed.真实世界中的急性髓细胞白血病：为什么需要基于人群的登记处。
Blood. 2012 Apr 26;119(17):3890-9. doi: 10.1182/blood-2011-12-379008. Epub 2012 Mar 1.
4
Use of cytarabine and idarubicin in a newly diagnosed AML patient with a severe wound.阿糖胞苷和伊达比星在一名新诊断的伴有严重伤口的急性髓系白血病患者中的应用。
Transfus Apher Sci. 2011 Aug;45(1):17-20. doi: 10.1016/j.transci.2011.06.016. Epub 2011 Jul 2.
5
Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study.随机研究诱导治疗比较标准剂量伊达比星与高剂量柔红霉素在初治成人急性髓细胞白血病患者: JALSG AML201 研究。
Blood. 2011 Feb 24;117(8):2358-65. doi: 10.1182/blood-2010-03-273243. Epub 2010 Aug 6.
6
Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10.柔红霉素与米托蒽醌和伊达比星对比作为成人急性髓系白血病的诱导和巩固化疗：EORTC 和 GIMEMA 组 AML-10 研究。
J Clin Oncol. 2009 Nov 10;27(32):5397-403. doi: 10.1200/JCO.2008.20.6490. Epub 2009 Oct 13.
7
Anthracycline dose intensification in acute myeloid leukemia.急性髓系白血病中蒽环类药物剂量强化
N Engl J Med. 2009 Sep 24;361(13):1249-59. doi: 10.1056/NEJMoa0904544.
8
Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia.诱导化疗后绝对淋巴细胞计数的恢复预示着急性髓系白血病患者有更好的生存率。
Leukemia. 2006 Jan;20(1):29-34. doi: 10.1038/sj.leu.2404032.
9
The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction.利妥昔单抗在B细胞慢性淋巴细胞白血病患者体内清除肿瘤细胞的机制：半胱天冬酶激活和凋亡诱导的证据。
Blood. 2002 Feb 1;99(3):1038-43. doi: 10.1182/blood.v99.3.1038.
10
Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study.核型分析可预测成人急性髓系白血病缓解前及缓解后治疗的结果：一项西南肿瘤协作组/东部肿瘤协作组的研究
Blood. 2000 Dec 15;96(13):4075-83.

[Clinical observation of standard IA regimen as induction chemotherapy in 242 patients with newly diagnosed acute myeloid leukemia].

作者信息

Huang J Y, Liu W X, Lian Y, Zhao H H, Wu H X, Lu H, Chen L J, He G S, Li J Y, Qian S X

机构信息

Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China.

出版信息

Zhonghua Xue Ye Xue Za Zhi. 2018 Apr 14;39(4):331-335. doi: 10.3760/cma.j.issn.0253-2727.2018.04.016.

DOI:10.3760/cma.j.issn.0253-2727.2018.04.016
PMID:29779333
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7342127/
Abstract
摘要